Comparative Pharmacology
Head-to-head clinical analysis: LOMAIRA versus MAZANOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMAIRA versus MAZANOR.
LOMAIRA vs MAZANOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lomitapide inhibits microsomal triglyceride transfer protein (MTP), which is responsible for the assembly and secretion of apolipoprotein B-containing lipoproteins in the liver and intestine, thereby reducing plasma levels of LDL-C, triglycerides, and other lipids.
Mazanor (mazindol) is a sympathomimetic amine that acts as an anorectic agent. It likely reduces appetite by increasing norepinephrine and dopamine levels in the hypothalamic feeding centers via reuptake inhibition and possibly by blocking serotonin receptors.
100 mg orally once daily, with or without food.
1 mg orally once daily, titrated based on response and tolerability up to 2 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 12 hours; clinical context: steady-state achieved in 2-3 days.
Terminal half-life is 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours).
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other.
Primarily renal (85-90% as unchanged drug), with minor biliary/fecal elimination (5-10%).
Category C
Category C
Appetite Suppressant
Appetite Suppressant